Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) EV/Assets Ratio: 2.75x

Is Zoetis Inc.’s EV/Assets ratio high or low?

Zoetis Inc.'s EV/Assets ratio of 2.75x is 53% below its 5-year average of 5.84x, near the low end of its 5-year range (2.55x–8.84x).

The EV/Assets ratio for Zoetis Inc. (ZTS) is 2.75x as of Wednesday, June 10, 2026. It is below its 12-month average by 35.48% (4.26x).

ZTS EV/Assets Ratio Chart

ZTS EV/Assets Ratio
2.75x-51.50% 1Y
Zoom

ZTS Average EV/Assets Ratio Chart

ZTS Current vs Average EV/Assets Ratio Chart

ZTS EV/Assets Ratio Metrics

EV/ASSETS RATIO

2.75x

EV/ASSETS RATIO AVG TTM

4.26x

EV/ASSETS RATIO AVG 3Y

5.44x

EV/ASSETS RATIO AVG 5Y

5.84x

EV/ASSETS RATIO AVG 10Y

5.47x

EV/ASSETS RATIO AVG 15Y

4.95x

EV/ASSETS RATIO AVG 20Y

4.95x

CURRENT VS TTM AVG

-35.48%

CURRENT VS 3Y AVG

-49.42%

CURRENT VS 5Y AVG

-52.87%

CURRENT VS 10Y AVG

-49.72%

CURRENT VS 15Y AVG

-44.39%

CURRENT VS 20Y AVG

-44.39%

ZTS Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Zoetis Inc. (ZTS)$34.20B2.75x4.26x5.44x5.84x
Centene Corporation (CNC)$31.94B0.33x0.25x0.39x0.51x
Agilent Technologies, Inc. (A)$37.17B2.98x3.06x3.38x3.71x
Medline Inc. (MDLN)$30.90B1.04x1.18x1.18x1.18x
IQVIA Holdings Inc. (IQV)$30.60B1.05x1.56x1.81x1.98x
DexCom, Inc. (DXCM)$29.24B4.53x4.23x5.88x7.47x
Biogen Inc. (BIIB)$29.00B1.10x0.95x1.19x1.43x
Veeva Systems Inc. (VEEV)$26.73B2.78x4.63x5.33x6.99x
Humana Inc. (HUM)$43.78B0.96x0.75x0.88x1.10x
IDEXX Laboratories, Inc. (IDXX)$44.47B13.69x15.32x13.69x15.18x

Zoetis Inc. EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Zoetis Inc. EV/Assets Ratio FAQ

What is the EV/Assets ratio for Zoetis Inc. (ZTS)?
The EV/Assets ratio for ZTS stock is 2.75x.
Is Zoetis Inc.'s EV/Assets ratio high or low?
Zoetis Inc.'s EV/Assets ratio of 2.75x is 53% below its 5-year average of 5.84x, near the low end of its 5-year range (2.55x–8.84x).
What is the TTM average EV/Assets ratio for Zoetis Inc. (ZTS)?
The TTM average EV/Assets ratio for ZTS stock is 4.26x.
What is the 3Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
The 3Y average EV/Assets ratio for ZTS stock is 5.44x.
What is the 5Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
The 5Y average EV/Assets ratio for ZTS stock is 5.84x.
What is the 10Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
The 10Y average EV/Assets ratio for ZTS stock is 5.47x.
What is the 15Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
The 15Y average EV/Assets ratio for ZTS stock is 4.95x.
What is the 20Y average EV/Assets ratio for Zoetis Inc. (ZTS)?
The 20Y average EV/Assets ratio for ZTS stock is 4.95x.

Zoetis Inc. EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-102.75x
2026-06-092.77x
2026-06-082.68x
2026-06-052.70x
2026-06-042.70x
2026-06-032.64x
2026-06-022.61x
2026-06-012.64x
2026-05-292.65x
2026-05-282.66x
2026-05-272.70x
2026-05-262.72x
2026-05-222.75x
2026-05-212.71x
2026-05-202.70x
2026-05-192.68x
2026-05-182.65x
2026-05-152.55x
2026-05-142.59x
2026-05-132.55x
2026-05-122.63x
2026-05-112.62x
2026-05-082.79x
2026-05-072.92x
2026-05-063.62x
2026-05-053.66x
2026-05-043.66x
2026-05-013.70x
2026-04-303.72x
2026-04-293.69x
2026-04-283.77x
2026-04-273.81x
2026-04-243.78x
2026-04-233.76x
2026-04-223.80x
2026-04-213.82x
2026-04-203.94x
2026-04-173.93x
2026-04-163.84x
2026-04-153.89x
2026-04-143.90x
2026-04-133.87x
2026-04-103.81x
2026-04-093.87x
2026-04-083.86x
2026-04-073.78x
2026-04-063.82x
2026-04-023.81x
2026-04-013.79x
2026-03-313.82x
2026-03-303.76x
2026-03-273.68x
2026-03-263.77x
2026-03-253.77x
2026-03-243.75x
2026-03-233.73x
2026-03-203.74x
2026-03-193.75x
2026-03-183.79x
2026-03-173.91x
2026-03-163.81x
2026-03-133.74x
2026-03-123.74x
2026-03-113.86x
2026-03-103.88x
2026-03-093.93x
2026-03-063.91x
2026-03-053.93x
2026-03-044.04x
2026-03-034.04x
2026-03-024.12x
2026-02-274.18x
2026-02-264.14x
2026-02-254.12x
2026-02-244.11x
2026-02-234.03x
2026-02-204.12x
2026-02-194.07x
2026-02-184.13x
2026-02-174.02x
2026-02-134.06x
2026-02-124.03x
2026-02-114.10x
2026-02-104.09x
2026-02-094.06x
2026-02-064.07x
2026-02-054.05x
2026-02-044.05x
2026-02-033.92x
2026-02-024.00x
2026-01-303.99x
2026-01-293.90x
2026-01-283.91x
2026-01-274.00x
2026-01-263.97x
2026-01-233.97x
2026-01-223.98x
2026-01-214.00x
2026-01-203.95x
2026-01-163.99x
2026-01-154.01x
2026-01-144.02x
2026-01-133.99x
2026-01-124.01x
2026-01-094.06x
2026-01-084.05x
2026-01-074.02x
2026-01-064.12x
2026-01-054.12x
2026-01-024.02x
2025-12-314.02x
2025-12-304.04x
2025-12-294.03x
2025-12-264.03x
2025-12-244.01x
2025-12-233.95x
2025-12-223.96x
2025-12-193.92x
2025-12-183.93x
2025-12-173.92x
2025-12-163.95x
2025-12-153.88x
2025-12-123.81x
2025-12-113.78x
2025-12-103.79x
2025-12-093.73x
2025-12-083.80x
2025-12-053.81x
2025-12-043.86x
2025-12-033.93x
2025-12-023.98x
2025-12-014.06x
2025-11-284.09x
2025-11-264.08x
2025-11-254.08x
2025-11-243.93x
2025-11-213.91x
2025-11-203.73x
2025-11-193.77x
2025-11-183.80x
2025-11-173.82x
2025-11-143.87x
2025-11-133.88x
2025-11-123.89x
2025-11-113.85x
2025-11-103.84x
2025-11-073.86x
2025-11-063.84x
2025-11-053.87x
2025-11-043.98x
2025-11-034.81x
2025-10-314.80x
2025-10-304.80x
2025-10-294.80x
2025-10-284.84x
2025-10-274.91x
2025-10-244.86x
2025-10-234.87x
2025-10-224.90x
2025-10-214.86x
2025-10-204.83x
2025-10-174.80x
2025-10-164.78x
2025-10-154.74x
2025-10-144.78x
2025-10-134.75x
2025-10-104.71x
2025-10-094.78x
2025-10-084.78x
2025-10-074.76x
2025-10-064.84x
2025-10-034.88x
2025-10-024.88x
2025-10-014.89x
2025-09-304.87x
2025-09-294.77x
2025-09-264.79x
2025-09-254.71x
2025-09-244.73x
2025-09-234.76x
2025-09-224.82x
2025-09-194.86x
2025-09-184.90x
2025-09-174.89x
2025-09-164.91x
2025-09-154.87x
2025-09-124.93x
2025-09-115.00x
2025-09-104.97x
2025-09-094.98x
2025-09-085.04x
2025-09-055.09x
2025-09-045.08x
2025-09-035.06x
2025-09-025.07x
2025-08-295.18x
2025-08-285.13x
2025-08-275.15x
2025-08-265.13x
2025-08-255.14x
2025-08-225.19x
2025-08-215.16x
2025-08-205.19x
2025-08-195.16x
2025-08-185.06x
2025-08-155.11x
2025-08-145.08x
2025-08-135.06x
2025-08-124.98x
2025-08-114.96x
2025-08-084.90x
2025-08-074.93x
2025-08-064.88x
2025-08-054.87x
2025-08-045.18x
2025-08-015.04x
2025-07-314.99x
2025-07-305.09x
2025-07-295.16x
2025-07-285.15x
2025-07-255.19x
2025-07-245.21x
2025-07-235.23x
2025-07-225.16x
2025-07-215.04x
2025-07-185.08x
2025-07-175.12x
2025-07-165.17x
2025-07-155.21x
2025-07-145.30x
2025-07-115.28x
2025-07-105.40x
2025-07-095.39x
2025-07-085.37x
2025-07-075.35x
2025-07-035.42x
2025-07-025.41x
2025-07-015.42x
2025-06-305.31x
2025-06-275.32x
2025-06-265.31x
2025-06-255.35x
2025-06-245.37x
2025-06-235.36x
2025-06-205.35x
2025-06-185.28x
2025-06-175.49x
2025-06-165.58x
2025-06-135.58x
2025-06-125.72x
2025-06-115.64x
2025-06-105.67x
2025-06-095.59x
2025-06-065.76x
2025-06-055.71x
2025-06-045.71x
2025-06-035.77x
2025-06-025.74x
2025-05-305.72x
2025-05-295.67x

Showing the most recent 260 of 3,359 data points. The chart above shows the full history.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck